Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04112381 · ClinicalTrials.gov registry record · NA

Bilateral Treatment of Medication Refractory Essential Tremor

A NA study of Essential Tremor, sponsored by InSightec.

Active
Registry status
NA
Development phase
51
Enrollment target
7
Study locations

NCT04112381 is a NA study of Essential Tremor that is active but no longer recruiting, run by InSightec. The registered enrollment target is 51 participants, below the 401-participant average among 41 other Essential Tremor trials with a reported enrollment target (87% lower). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04112381, a NA study of Essential Tremor, is active but no longer recruiting, sponsored by InSightec.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
51 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to see if the MR-guided focused ultrasound (MRgFUS) thalamotomy procedure can be performed on both sides of the brain safely and effectively to reduce bilateral tremor.

Conditions Studied

Interventions

  • DEVICE Exablate Model 4000 Type 1.0/1.1

Study Locations (7)

California

  • Stanford University, School of Medicine - Stanford

Maryland

  • University of Maryland - Baltimore

New York

  • Weill Cornell Medicine - New York

Ohio

  • The Ohio State University - Wexner Medical Center - Columbus

Pennsylvania

  • University of Pennsylvania - Philadelphia

Virginia

  • University of Virginia - Charlottesville

West Virginia

  • West Virginia University - Morgantown

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2020-06-30
Est. Completion 2026-06
Phase NA

Sponsor

InSightec

38 total trials

What the Registry Record Tells You About NCT04112381

The ClinicalTrials.gov registry entry for NCT04112381 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 401-participant average among 41 other Essential Tremor trials with a reported enrollment target (87% lower). The listed sponsor is InSightec, which has 38 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Essential Tremor appearing as the primary indexed condition, and to 1 intervention - of which Exablate Model 4000 Type 1.0/1.1 is the first listed.

NCT04112381 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Maryland, New York.

Frequently Asked Questions

What is clinical trial NCT04112381 about?

NCT04112381 is a clinical study titled "Bilateral Treatment of Medication Refractory Essential Tremor". The purpose of this study is to see if the MR-guided focused ultrasound (MRgFUS) thalamotomy procedure can be performed on both sides of the brain safely and effectively to reduce bilateral tremor.

What is the current status of trial NCT04112381?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 51 participants. The study started on 2020-06-30. Estimated completion is 2026-06.

What conditions does trial NCT04112381 study?

This clinical trial studies the following conditions: Essential Tremor.

What interventions are being tested in trial NCT04112381?

The interventions under investigation include: Exablate Model 4000 Type 1.0/1.1 (DEVICE).

Who is sponsoring clinical trial NCT04112381?

This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04112381 being conducted?

This trial has 7 study locations across California, Maryland, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Essential Tremor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.